Low-Invasive, Positive-Pressure Pleural Drainage System(MIPPD)
The Final Piece to Complete the Successful “MicroVent® V3” Ecosystem.
This catheter is not a standalone device. It is the next-generation solution that, when combined with the already regulatory-approved and commercially successful “MicroVent® V3” ventilator, fundamentally solves the issues of “pain” and “lowered QOL” in traditional chest drainage. This technology represents the next pillar of revenue for a proven business success.
Built on a Proven Platform
Powered by the PMDA-approved “MicroVent® V3,” significantly reducing risks related to technical feasibility and safety.
Recurring Revenue from Consumables
This catheter is a disposable product requiring regular replacement, establishing a stable, recurring revenue model when paired with the core device.
Established Sales Channels
Enables rapid market entry and sales growth by leveraging the distribution network of the existing partner (Tochigi Seiko).
The Challenge: Traditional Methods Severely Impact QOL
Hard, cylindrical tubes cause patients persistent pain, while bulky water-seal devices restrict their freedom, creating a major barrier to home healthcare.
The Solution: A Low-Invasive, Positive-Pressure System
The soft, sheet-like catheter drastically reduces pain, and the compact, power-free MicroVent® V3 liberates patients from cumbersome equipment, enabling high-quality drainage at home and dramatically improving QOL.
A High-Certainty Business Value
The core device, MicroVent® V3, already generates an annual license value of approx. JPY 50 million. As a required consumable, this catheter has the potential for equal or greater revenue streams. The total value of the system is reasonably estimated to be in the JPY 300 Million to 1 Billion range. For an existing partner, this represents an unparalleled opportunity to maximize the value of their product line.